Psychiatric comorbidity in substitution treatment of opioid-dependent patients in primary care: Prevalence and impact on clinical features

Heroin Addiction and Related Clinical Problems

Volumn 12, Issue 4, 2010, Pages 5-16

  Lieb, Martin ^a   Wittchen, Hans Ulrich ^b   Palm, Ulrich ^a   Apelt, Sabine M ^b   Siegert, Jens ^b   Soyka, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Buprenorphine; Comorbidity; Drug dependence; EuropASI; Maintenance treatment; Methadone; Psychopathology; Substitution

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ACUTE STRESS DISORDER; ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; BORDERLINE STATE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OPIATE ADDICTION; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOPATHY; RISK REDUCTION; SCHIZOPHRENIA; SEX DIFFERENCE; SLEEP DISORDER; SOMATOFORM DISORDER;

EID: 78651418914     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wittchen HU, Apelt SM, Bühringer G, Gastpar M, Backmund M, Golz J, Kraus MR, Tretter F, Klotsche J, Siegert J, Pittrow D, Soyka M: Buprenorphine and Methadone in the treatment of opioid dependence: methods and design of the COBRA study. Int J Methods Psychiatr Res 2005;14:14-28.
2. Bundesministerium für Gesundheit und soziale Sicherung: Drogen- und Suchtbericht 2005. Berlin, Bundesministerium für Gesundheit und soziale Sicherung, 2005:76.
3. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Co-morbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 2000;264:2511-2518.
4. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51(1):8-19.
5. Woody GE, McLellan AT, Luborsky L, O'Brien CP: Sociopathy and psychotherapy outcome. Arch Gen Psychiatry 1985;42(11):1081-1086.
6. Woody GE, Luborsky L, McLellan AT, O'Brien CP, Bexk AT, Blaine J, Herman I, Hole A: Psychotherapy for opiate addicts. Arch Gen Psychiatry 1983;40:636-645.
7. Rounsaville BJ, Weismann MM, Kleber H, Wilber C: Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1992;39:161-166.
8. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE: Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997;54(1):71-80.
9. Kessler RC: Impact of substance abuse on the diagnosis, course and treatment outcome of mood disorders. Biol Psychiatry 2004;56:730-737.
10. European Monitoring Centre for Drugs and Drug Addiction: Annual report 2004: The state of the drugs problem in the European Union and Norway. Luxembourg, European Monitoring Centre for Drugs and Drug Addiction, 2004.
11. King VL, Kidorf MS, Stoller KB, Brooner RK: Influence of psychiatric comorbidity on HIV risk behaviors: changes during drug abuse treatment. J Addict Disorder 2004;19:65-83.
12. Woody GE, Metzger D, Navaline H, McLellan T, O'Brien CP: Psychiatric symptoms, risky behavior and HIV infection. NIDA Res Monogr 1997;172:156-170.
13. Kleinman PH, Millman RB, Robinson H, Lesser M, Hsu C, Engelhart P, Finkelstein I.: Lifetime needle sharing: a predictive analysis. J Subst Abuse Treat 1994;11:449-455.
14. Tourian K, Alterman A, Metzger D, Rutherford M, Cacciola JS, McKay JR: Validity of three measures of antisociality in predicting HIV risk behaviors in methadone-maintenance patients. Drug Alcohol Depend 1997;47:99-107.
15. Brooner RK, Greenfield L, Schmidt CW, Bigelow GE: Antisocial personality disorder and HIV infection among intravenous drug abusers. Am J Psychiatry 1993;150:53-58.
16. Darke S, Hall W, Swift W: Prevalence, symptoms and correlates of antisocial personality disorder among methadone maintenance clients. Drug Alcohol Depend. 1994;34:253-257.
17. Rutherford MJ, Cacciola JS, Alterman AI: Relationships of personality disorders with problem severity in methadone patients. Drug Alcohol Depend 1994;35:69-76.
18. Brienza RS, Stein MD, Chen M, Gogineni A, Sobota M, Maksad J, Hu P, Clarke J: Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat 2000;18:331-337.
19. Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphine treatment of refractory depression, J Clin Psychopharm 2005;15:49-57.
20. Emrich HM, Vogt P, Herz A: Possible antidepressant effects of opioids: action of Buprenorphine. Ann NY Acad Sci 1982;398:108-112.
21. Kosten TR, Morgan C Kosten TA: Depressive symptoms during Buprenorphine treatment of opioid abusers. J Subst Abuse Treat 1992;7:51-54.
22. Dean AJ, Bell J, Christie MJ, Mattick RP: Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry 2004;19(8):510-513.
23. Dittert S, Naber D, Soyka M: Methadone substitution and ability to drive. Results of an experimental study (in German). Nervenarzt 1999;70:457-462.
24. Kagerer S, Backmund M, Walcher S, Soyka M: Substitution mit Buprenorphin und Fahrtauglichkeit - Ergebnisse einer experimentellen Untersuchung. Suchtmed 2002;4: 17-24.
25. Lenné MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ: The effects of the opioid pharmacotherapies methadone, LAAM and Buprenorphine, alone and in combination with alcohol, on stimulated driving. Drug Alcohol Depend 2003;72:271-278.
26. Shindler SD, Ortner R, Peternell A, Eder H, Opgenoorth E, Fischer G: Maintenance Therapy with Synthetic Opioids and Driving Aptitude. Eur Addict Res 2004;10:80-97.
27. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H: Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine maintained than in methadone maintained patients. J Clin Psychopharmacol 2005;25:490-493.
28. Gsellhofer B, Küfner H, Vogt M, Weiler D: European Addiction Severity Index - EuropASI. Manual for training and execution. Stuttgart, Schneider, 1999.
29. Wittchen HU: Reliability and validity studies of the WHO - Composite International Diagnostic interview (CIDI): a critical review. J Psychiatric Res 1994;28:57-84.
30. Krausz M, Verthein U, Degkwitz P: Prevalence of psychiatric disorders in opiate dependent patients in contact with the drug treatment system. Nervenarzt. 1998;69:557-567.
31. Bleich A, Gelkopf M, Schmidt V, Hayward R, Bodner G, Adelson M: Correlates of benzodiazepine abuse in methadone maintenance treatment. A 1 year prospective study in an Israeli clinic. Addiction 1999;94:1533-1540.
32. Ross J, Darke S: The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction 2000;95:1785-1793.
33. Epstein DH, Preston KL: Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003;98:269-279.
34. Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A: Cannabis abuse is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic. Aust N Z J Psychiatry 2004;38:42-46.
35. Power K, DeMartino R: Co-occurring disorders and achieving recovery: the substance abuse and mental health services administration perspective. Biol Psychiatry 2004;56:721-722.